Compare Cytokinetics Inc (CYTK) vs ON Holding AG (ONON) Price & Performance

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

ONON shares plunged 19.52% to $31.21 after Q2 2026 earnings revealed a rare revenue miss and reduced full-year growth guidance, despite beating EPS estimates. The stock now trades near key support at $30 with bearish technical indicators dominating. Fundamentally, the company maintains strong profitability with 64.82% gross margins and 23.95% ROE, but wholesale channel weakness and cautious consumer spending have tempered growth expectations.

While current valuation multiples appear reasonable (P/E 21.17, P/S 5), the stock faces near-term headwinds from growth deceleration. Analyst consensus remains bullish with a $52.86 price target representing 69% upside, but investors should monitor Q3 earnings execution and wholesale recovery for confirmation of the investment thesis.